Published on

Medicine – Drug Therapies in HIV Infection

Drug treatment of human immunodeficiency virus (HIV) infection has two major objectives: suppression of viral replication through antiretroviral therapy (ART) and prevention of opportunistic infections in patients with significant immunosuppression.

Major Components of HIV Drug Therapy
  1. Antiretroviral therapy (ART).
  2. Prevention of opportunistic infections.
  3. Monitoring treatment response and adverse effects.
  4. Management of drug interactions and resistance.

1. Overview of HIV Drug Therapy

HIV Infection Antiretroviral Therapy Opportunistic Infection Prevention Suppresses viral replication Reduces risk of opportunistic infections Improved Clinical Outcomes

2. Antiretroviral Therapy (ART)

A. When Should ART Be Started?

Older HIV treatment guidelines recommended starting antiretroviral therapy when the CD4 count fell below 350 cells/mm³ or when the viral load was particularly high.

This approach is now outdated.

Current Treatment Principle

ART is recommended for all people diagnosed with HIV, regardless of CD4 count or viral load, and should generally be initiated as soon as feasible.

Benefits of Early ART

  • Prevents progression to AIDS.
  • Reduces opportunistic infections.
  • Reduces HIV-associated malignancies.
  • Preserves and restores CD4+ T-cell function.
  • Improves life expectancy.
  • Prevents sexual transmission when sustained viral suppression is achieved.

ART timing requires special consideration in selected opportunistic infections, particularly cryptococcal meningitis and tuberculosis meningitis, because early treatment may increase the risk of serious immune reconstitution inflammatory syndrome (IRIS).

Examination Point: ART is now recommended for all patients with HIV, rather than waiting until the CD4 count falls below 350 cells/mm³.

B. Aims of ART

The primary aim of ART is to achieve and maintain suppression of plasma HIV RNA to undetectable levels on standard clinical assays.

Additional Objectives

  • Restore immune function.
  • Increase or preserve CD4 count.
  • Prevent progression to AIDS.
  • Reduce morbidity and mortality.
  • Prevent HIV transmission.
  • Improve long-term quality of life.

Illustration: Effects of ART

Combination ART Inhibition of HIV Replication Sustained Viral Suppression CD4 Recovery Reduced HIV-Related Disease

ART does not eradicate HIV because the virus persists in long-lived cellular reservoirs. Consequently, treatment is generally lifelong.

C. Combination Therapy

Traditional HIV treatment used combinations of three or sometimes four antiretroviral drugs.

Most contemporary initial regimens use three active drugs from at least two drug classes.

A common regimen consists of:

  • Two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).
  • One integrase strand transfer inhibitor (INSTI).

Selected patients may receive recommended two-drug regimens, such as dolutegravir plus lamivudine, when appropriate eligibility criteria are met.

Advantages of Combination Therapy

  • Potent suppression of viral replication.
  • Reduced emergence of drug resistance.
  • Improved immune recovery.
  • Reduced HIV-associated complications.
Examination Point: Modern initial ART commonly consists of two NRTIs plus an INSTI.

3. Classes of Antiretroviral Drugs

A. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

NRTIs inhibit HIV reverse transcriptase, the enzyme responsible for converting viral RNA into DNA.

They act as defective nucleotide building blocks, causing termination of viral DNA synthesis.

Examples

  • Zidovudine (AZT).
  • Lamivudine (3TC).
  • Emtricitabine (FTC).
  • Abacavir (ABC).
  • Tenofovir disoproxil fumarate (TDF).
  • Tenofovir alafenamide (TAF).

Important Adverse Effects

Drug Important Adverse Effects or Precautions
ZidovudineAnaemia, neutropenia, myopathy
LamivudineGenerally well tolerated
AbacavirHypersensitivity; HLA-B*57:01 testing required before use
Tenofovir DFRenal toxicity, reduced bone mineral density
Tenofovir AFLess renal and bone toxicity than TDF; different metabolic effects

Older NRTIs may cause mitochondrial toxicity, including lactic acidosis and pancreatitis.

Examination Point: NRTIs inhibit reverse transcriptase through viral DNA chain termination.

B. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

NNRTIs inhibit reverse transcriptase by binding to an allosteric site on the enzyme.

Unlike NRTIs, they do not require intracellular phosphorylation to become active.

Examples

  • Nevirapine.
  • Efavirenz.
  • Rilpivirine.
  • Doravirine.
  • Etravirine.

Important Adverse Effects

  • Skin rash.
  • Hepatotoxicity.
  • Drug interactions.
  • Neuropsychiatric effects, particularly with efavirenz.

Nevirapine can cause severe hepatotoxicity and hypersensitivity reactions.

Examination Point: NNRTIs inhibit reverse transcriptase through allosteric binding.

C. Protease Inhibitors (PIs)

Protease inhibitors block the HIV protease enzyme, preventing cleavage of viral polyproteins into functional proteins.

This produces immature, noninfectious viral particles.

Examples

  • Darunavir.
  • Atazanavir.
  • Lopinavir.
  • Ritonavir.
  • Indinavir.

Ritonavir is commonly used at low doses as a pharmacokinetic booster rather than as the principal active antiretroviral agent.

Indinavir and some older protease inhibitors are now used infrequently.

Important Adverse Effects

  • Gastrointestinal disturbance.
  • Dyslipidaemia.
  • Insulin resistance.
  • Drug–drug interactions.
  • Hyperbilirubinaemia with atazanavir.
  • Nephrolithiasis with indinavir.
Examination Point: Protease inhibitors prevent viral maturation by inhibiting cleavage of HIV polyproteins.

D. Fusion Inhibitors

Fusion inhibitors prevent HIV from fusing with the host cell membrane.

The classical example is enfuvirtide (T-20).

Enfuvirtide binds to the viral gp41 protein, preventing membrane fusion and viral entry.

Important Characteristics

  • Administered by subcutaneous injection.
  • Primarily used in selected treatment-experienced patients.
  • Injection-site reactions are common.
Examination Point: Enfuvirtide inhibits HIV entry by targeting gp41-mediated membrane fusion.

E. Integrase Strand Transfer Inhibitors (INSTIs)

INSTIs are now central to many first-line ART regimens.

They inhibit HIV integrase, preventing the insertion of viral DNA into the host genome.

Examples

  • Dolutegravir.
  • Bictegravir.
  • Raltegravir.
  • Cabotegravir.

Important Considerations

  • High antiviral efficacy.
  • Generally good tolerability.
  • Drug interactions with polyvalent cations.
  • Possible weight gain with some regimens.
  • Occasional neuropsychiatric adverse effects.
Examination Point: INSTIs prevent integration of HIV DNA into the host genome.

F. Other Entry and Attachment Inhibitors

Additional agents may be used in selected patients, particularly those with multidrug-resistant HIV.

  • Maraviroc: CCR5 antagonist.
  • Fostemsavir: gp120 attachment inhibitor.
  • Ibalizumab: post-attachment inhibitor.
  • Lenacapavir: capsid inhibitor that disrupts multiple stages of the HIV life cycle.

These drugs are not interchangeable with standard first-line regimens. Selection depends on clinical indications, resistance testing and other factors.

4. Where Antiretroviral Drugs Act in the HIV Life Cycle

1. Attachment and Entry CCR5 / Attachment Inhibitors 2. Membrane Fusion Enfuvirtide (gp41) 3. Reverse Transcription NRTIs and NNRTIs 4. Integration into Host DNA Integrase Inhibitors 5. Viral Gene Expression Viral RNA and Protein Production 6. Assembly and Budding Production of Immature Virions 7. Viral Maturation Protease Inhibitors Capsid inhibitors affect multiple stages.

Simplified HIV replication cycle and major antiretroviral drug targets.

Stage Drug Class Example
Attachment and entryCCR5 antagonists, attachment inhibitorsMaraviroc, fostemsavir
Membrane fusionFusion inhibitorsEnfuvirtide
Reverse transcriptionNRTIsZidovudine, lamivudine, tenofovir
Reverse transcriptionNNRTIsEfavirenz, nevirapine
IntegrationINSTIsDolutegravir, bictegravir
Viral maturationProtease inhibitorsDarunavir, atazanavir

5. Prevention of Opportunistic Infections

Effective ART is the most important long-term intervention for preventing HIV-associated opportunistic infections.

Additional antimicrobial prophylaxis may be indicated according to CD4 count, viral load, previous opportunistic infections and other risk factors.

A. Pneumocystis jirovecii Pneumonia (PCP) Prophylaxis

PCP is an AIDS-defining fungal infection, particularly associated with CD4 counts below 200 cells/mm³.

Indications for Primary Prophylaxis

Under commonly used adult HIV guidelines, primary PCP prophylaxis is indicated when:

  • CD4 count is below 100 cells/mm³, regardless of viral load.
  • CD4 count is between 100 and 200 cells/mm³ and plasma HIV RNA remains detectable.

Some local guidelines use a simpler threshold of CD4 below 200 cells/mm³.

B. Co-trimoxazole (TMP-SMX)

Co-trimoxazole, also called trimethoprim-sulfamethoxazole (TMP-SMX), is the preferred agent for PCP prophylaxis.

Common Prophylactic Regimen

One double-strength tablet containing 160 mg trimethoprim and 800 mg sulfamethoxazole orally once daily is a commonly used regimen.

Advantages

  • Prevents PCP.
  • Provides additional protection against toxoplasmosis when the appropriate regimen is used.
  • Has activity against some bacterial infections.

Important Adverse Effects

  • Skin rash.
  • Bone marrow suppression.
  • Hyperkalaemia.
  • Renal-related adverse effects.
Examination Point: Co-trimoxazole is the preferred drug for PCP prophylaxis and can also protect against toxoplasmosis.

C. Pentamidine

Aerosolised pentamidine may be used as an alternative when TMP-SMX cannot be tolerated and other suitable options are unavailable or inappropriate.

Common Prophylactic Regimen

Aerosolised pentamidine 300 mg by inhalation every four weeks is a commonly used regimen.

Limitations

  • Less comprehensive protection than TMP-SMX.
  • Does not prevent toxoplasmosis.
  • May cause cough and bronchospasm.
  • Requires specialised nebuliser administration.

Other alternatives include atovaquone and dapsone-based regimens. G6PD testing is required before dapsone use.

Examination Point: Aerosolised pentamidine is an alternative for PCP prophylaxis but does not provide protection against toxoplasmosis.

D. When Can PCP Prophylaxis Be Stopped?

Primary PCP prophylaxis can generally be discontinued after effective ART produces sustained immune recovery, commonly when the CD4 count rises to at least 200 cells/mm³ for three months or longer.

Selected patients with CD4 counts between 100 and 200 cells/mm³ and sustained undetectable viral loads may also be eligible for discontinuation under specialist guidance.

Illustration: PCP Prophylaxis Pathway

HIV with Significant Immunosuppression Assess CD4 Count, Viral Load and Previous PCP Start TMP-SMX Prophylaxis When Indicated Effective ART and CD4 Recovery Reassess Need for Prophylaxis

6. Other Important Opportunistic Infection Prophylaxis

Infection Typical Indication Prevention
PCPSignificant CD4 depletion, commonly below 200 with guideline-specific viral-load criteriaTMP-SMX
Toxoplasma encephalitisCD4 below 100 and positive Toxoplasma IgGTMP-SMX
Disseminated MACCD4 below 50 when effective suppressive ART is not being promptly initiated, after excluding active MACAzithromycin or clarithromycin
Latent tuberculosisPositive screening or qualifying exposure after active TB is excludedAppropriate TB preventive therapy

Routine primary prophylaxis against disseminated MAC is generally unnecessary when effective ART is initiated promptly.

7. Comparison of Antiretroviral Drug Classes

Drug Class Mechanism Examples Important Adverse Effects
NRTIsViral DNA chain terminationZidovudine, lamivudine, tenofovirBone marrow, renal or bone toxicity depending on drug
NNRTIsAllosteric reverse transcriptase inhibitionEfavirenz, nevirapineRash, hepatotoxicity, neuropsychiatric effects
PIsInhibit viral protein cleavage and maturationDarunavir, atazanavir, ritonavirMetabolic effects, drug interactions
Fusion inhibitorsInhibit gp41-mediated fusionEnfuvirtideInjection-site reactions
INSTIsInhibit viral DNA integrationDolutegravir, bictegravirDrug interactions, possible weight gain
CCR5 antagonistsBlock CCR5-mediated entryMaravirocDrug interactions; requires suitable viral tropism

8. High-Yield Examination Summary

Antiretroviral Therapy

  • ART is recommended for all people with HIV, regardless of CD4 count.
  • The primary aim is sustained viral suppression.
  • Standard initial treatment commonly consists of two NRTIs plus an INSTI.
  • ART suppresses HIV but does not eradicate latent viral reservoirs.

Drug Mechanisms

  • NRTIs: inhibit viral DNA synthesis through chain termination.
  • NNRTIs: allosterically inhibit reverse transcriptase.
  • PIs: inhibit viral maturation.
  • Fusion inhibitors: block viral entry through gp41.
  • INSTIs: prevent integration of viral DNA into host DNA.

Opportunistic Infection Prevention

  • Co-trimoxazole is the preferred PCP prophylactic agent.
  • Aerosolised pentamidine is an alternative but does not prevent toxoplasmosis.
  • PCP prophylaxis is particularly relevant in patients with CD4 counts below 200 cells/mm³.
  • Effective ART and immune restoration reduce the need for ongoing prophylaxis.
Most Important Examination Point

The older recommendation to initiate ART only when CD4 falls below 350 cells/mm³ is obsolete. Modern treatment recommends ART for everyone with HIV. For PCP prevention, co-trimoxazole remains the preferred prophylactic agent, with eligibility determined by CD4 count, viral suppression and clinical history.

Clinical Note

Antiretroviral regimens and opportunistic infection prophylaxis require individual assessment of resistance, coinfections, renal and hepatic function, drug interactions and current local guidelines. Patients should not stop or modify ART without medical supervision.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments